Vuorela Pia, Ala-Mello Sirpa, Saloranta Carola, Penttinen Maila, Pöyhönen Minna, Huoponen Kirsi, Borozdin Wiktor, Bausch Birke, Botzenhart Elke M, Wilhelm Christian, Kääriäinen Helena, Kohlhase Jürgen
Department of Medical Genetics, University of Turku, Turku, Finland.
Genet Med. 2007 Oct;9(10):690-4. doi: 10.1097/gim.0b013e318156e68e.
Autosomal dominant CHARGE syndrome (OMIM no. 214800) is characterized by choanal atresia or cleft lip or palate, ocular colobomas, cardiovascular malformations, retardation of growth, ear anomalies, and deafness, and is caused by mutations in the CHD7 gene. Here, we describe the outcome of a molecular genetic analysis in 18 Finnish and 56 German patients referred for molecular confirmation of the clinical diagnosis of suspected CHARGE syndrome.
Quantitative real-time polymerase chain reaction or multiplex ligation-dependent probe amplification assays did not reveal deletions in mutation negative cases, suggesting that larger CHD7 deletions are not a major cause of CHARGE syndrome.
In this group of 74 patients, we found mutations in 30 cases. 22 mutations were novel, including 11 frameshift, 5 nonsense, 3 splice-site, and 3 missense mutations. One de novo frameshift mutation was found in the last exon and is expected to result in a minimally shortened CHD7 polypeptide. Because the mutation is associated with a typical CHARGE syndrome phenotype, it may indicate the presence of an as yet unknown functional domain in the very carboxyterminal end of CHD7.
Our mutation detection rate of 40.5% is reflective of screening an unselected sample population referred for CHD7 testing based on suspected clinical diagnosis of CHARGE syndrome and not for having met strict clinical criteria for this disorder.
常染色体显性遗传的CHARGE综合征(OMIM编号214800)的特征为后鼻孔闭锁或唇腭裂、眼裂、心血管畸形、生长发育迟缓、耳部异常和耳聋,由CHD7基因突变引起。在此,我们描述了对18名芬兰患者和56名德国患者进行分子遗传学分析的结果,这些患者因疑似CHARGE综合征的临床诊断需进行分子确认而被转诊。
定量实时聚合酶链反应或多重连接依赖探针扩增检测未在突变阴性病例中发现缺失,这表明较大的CHD7缺失不是CHARGE综合征的主要病因。
在这74名患者中,我们在30例中发现了突变。22种突变是新发现的,包括11种移码突变、5种无义突变、3种剪接位点突变和3种错义突变。在最后一个外显子中发现了一个新生的移码突变,预计会导致CHD7多肽轻微缩短。由于该突变与典型的CHARGE综合征表型相关,它可能表明在CHD7的羧基末端存在一个尚未知晓的功能域。
我们40.5%的突变检测率反映了对基于CHARGE综合征疑似临床诊断而转诊进行CHD7检测的未经过筛选的样本群体进行的筛查,而非针对符合该疾病严格临床标准的患者。